Logo
x

Search

Subscribe Now

Valneva

Valneva and Pfizer Present P-II (VLA15-221) Study Data of VLA15 Vaccine for Lyme Disease

Valneva and Pfizer Present P-II (VLA15-221) Study Data of VLA15 Vaccine for Lyme Disease

  • September 3, 2024
Valneva and LimmaTech Biologics Join Forces to Develop Shigella4V Against Shigellosis

Valneva and LimmaTech Biologics Join Forces to Develop Shigella4V Against Shigellosis

  • August 1, 2024
Valneva Reports EMA Acceptance of VLA1553 for Chikungunya

Valneva Reports EMA Acceptance of VLA1553 for Chikungunya

  • November 27, 2023
Valneva and Pfizer Report P-II Study (VLA15-221) Results of VLA15 for Lyme Disease in Pediatric and Adolescent

Valneva and Pfizer Report P-II Study (VLA15-221) Results of VLA15 for Lyme Disease in Pediatric and Adolescent

  • September 7, 2023
Valneva Reports P-III (VLA2001-301) Cov-Compare Study Results of VLA2001 (COVID-19 Vaccine) for COVID-19

Valneva Reports P-III (VLA2001-301) Cov-Compare Study Results of VLA2001 (COVID-19 Vaccine) for COVID-19

  • August 30, 2022
Valneva and Pfizer Report Results of VLA15 in P-II (VLA15-221) Trial for the Treatment of Lyme Disease

Valneva and Pfizer Report Results of VLA15 in P-II (VLA15-221) Trial for the Treatment of Lyme Disease

  • April 26, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.